In vivo, STK11 reactivation in an STK11-deficient/KRAS mutant lung cancer model markedly reduces tumour burden, abrogates increased glucose avidity that coincides with tumour progression and downregulates glycolysis-related genes and genes relating to mTOR signalling, consistent with its role in inhibiting mTOR in this context17. This evidence concerns the gene KRAS and lung carcinoma.